Improving Fat-Based Nanoparticles for Safe and Flexible RNA Delivery to the Lungs and Disease Treatment

Lipid-392 stLNP shows over a 100-fold improvement in lung delivery efficiency compared to its initial formulation.

• The targeting specificity of Lipid-392 stLNP reaches up to 99%, indicating precise pulmonary targeting.
• The formulation was well tolerated at a high dose of 12 mg/kg.
• In vivo studies demonstrate gene editing efficiencies of approximately 70% in both endothelial and epithelial cells.
• Repeated administrations maintain mRNA delivery efficiency, suggesting suitability for multidose therapies.
• In an acute lung injury model, delivery of IL-10 mRNA significantly reduces the inflammatory response.
• Lipid-392 stLNP efficiently co-delivers mRNA and siRNA, with a median effective dose of around 0.05 mg/kg.

Simplified